ArticleInfection and immunity2001
Immunoglobulin A-mediated protection against Bordetella pertussis infection.
Article in Infection and immunity, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 117 citations in OpenAlex.
- Pooled it
- Pooled it
- Immunological insights into why pertussis continues to be endemic.Human vaccines & immunotherapeutics · 2026Review
- Exposure tobioRxiv : the preprint server for biology · 2026Article
- A BcfA-containing intranasal vaccine generated TNPJ vaccines · 2026Article
- Review
- Article
- Nasal immunization with compound 48/80-adjuvanted acellular pertussis vaccines is an effective strategy to induce pertussis-specific systemic and mucosal immunity.Clinical and experimental vaccine research · 2025Article
- Mucosal IgA Antibodies are Critical for Bacterial Clearance ofPathogens & immunity · 2025Article
- A novel outer membrane vesicle adjuvant improves vaccine protection against Bordetella pertussis.NPJ vaccines · 2024Article
- Review
- Characterization of human Fc alpha receptor transgenic mice: comparison of CD89 expression and antibody-dependent tumor killing between mouse strains.Cancer immunology, immunotherapy : CII · 2023Article
- Recombinant-attenuated Salmonella enterica serovar Choleraesuis vector expressing the PlpE protein of Pasteurella multocida protects mice from lethal challenge.BMC veterinary research · 2023Article
- Generating enhanced mucosal immunity againstFrontiers in immunology · 2023Article
- Polyfunctional antibodies: a path towards precision vaccines for vulnerable populations.Frontiers in immunology · 2023Review
- Adjuvant Efficacy of the ECMS-Oil on Immune Responses againstJournal of immunology research · 2023Article
- Oral Immunization with AttenuatedMicrobiology spectrum · 2022Article
- Immunoglobulin A antibody composition is sculpted to bind the self gut microbiome.Science immunology · 2022Article
- Mucosal Immunization with DTaP Confers Protection againstInfection and immunity · 2021Article
- Combinatorial liposomal peptide vaccine induces IgA and confers protection against influenza virus and bacterial super-infection.Clinical & translational immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infection with Bordetella pertussis, the causative agent of pertussis (whooping cough) in humans, is followed by the production of antibodies of several isotypes, including immunoglobulin A (IgA). Little is known, however, about the role of IgA in immunity against pertussis. Therefore, we studied targeting of B. pertussis to the myeloid receptor for IgA, FcalphaRI (CD89), using either IgA purified from immune sera of pertussis patients or bispecific antibodies directed against B. pertussis and FcalphaRI (CD89 BsAb). Both IgA and CD89 BsAb facilitated FcalphaRI-mediated binding, phagocytosis, and bacterial killing by human polymorphonuclear leukocytes (PMNL) and PMNL originating from human FcalphaRI-transgenic mice. Importantly, FcalphaRI targeting resulted in enhanced bacterial clearance in lungs of transgenic mice. These data support the capacity of IgA to induce anti-B. pertussis effector functions via the myeloid IgA receptor, FcalphaRI. Increasing the amount of IgA antibodies induced by pertussis vaccines may result in higher vaccine efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.